Bespoke Gene Therapy 'Regulatory-as-a-Service'
FDA unveils rules for bespoke gene therapies, predicting a flood of rare disease applications via a new 'plausible mechanism' pathway.
sagaregcliff
Opportunity
75
Confidence
92
Country
Brazil
Weekly published opportunity pulse with country breakout, lane clustering, and evidence-backed opportunity cards.
FDA unveils rules for bespoke gene therapies, predicting a flood of rare disease applications via a new 'plausible mechanism' pathway.
Abridge is integrating NEJM and JAMA data to move from passive transcription to active clinical decision support.